Key statistics
On Friday, Cullinan Therapeutics Inc (CGEM:NSQ) closed at 16.02, 109.69% above the 52 week low of 7.64 set on Dec 12, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.84 |
---|---|
High | 16.45 |
Low | 15.67 |
Bid | 15.56 |
Offer | 17.28 |
Previous close | 15.58 |
Average volume | 404.98k |
---|---|
Shares outstanding | 57.98m |
Free float | 54.70m |
P/E (TTM) | -- |
Market cap | 928.79m USD |
EPS (TTM) | -3.10 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
- Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
- Cullinan Therapeutics to Participate in Fireside Chat at Stifel 2024 Healthcare Conference
- Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024
- Cullinan Therapeutics Receives U.S. FDA Clearance of Investigational New Drug Application for CLN-978 Administered Subcutaneously in Patients with Moderate to Severe Systemic Lupus Erythematosus
- Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus
- Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus
- Cullinan Therapeutics Presents Positive Updated Data from Module C of Zipalertinib Pivotal Phase 2b Study at ESMO 2024
- Cullinan Therapeutics to Participate in Upcoming Investor Conferences
- Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
More ▼